Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
暂无分享,去创建一个
D. Altieri | T. Griffith | N. Wall | Richard D. Williams | A. Sandler | David L. Scott | T. Azuhata | Jonathan M. Fialkov | D. Scott
[1] J. Li,et al. Cancer gene therapy using a survivin mutant adenovirus. , 2001, The Journal of clinical investigation.
[2] C. Gerharz,et al. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan , 2000, Cell Death and Differentiation.
[3] A. Kraft,et al. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). , 2000, Anticancer research.
[4] Haibin Xia,et al. A simple method for the rapid generation of recombinant adenovirus vectors , 2000, Gene Therapy.
[5] P. Hersey,et al. Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.
[6] R. Figlin,et al. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. , 2000, The cancer journal from Scientific American.
[7] E. Bröcker,et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.
[8] B. Gliniak,et al. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.
[9] J. McNiff,et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.
[10] Fengzhi Li,et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function , 1999, Nature Cell Biology.
[11] R. Weiss,et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, The New England journal of medicine.
[12] B. Oh,et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.
[13] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[14] K. Okumura,et al. Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of Type I IFNs , 1999, The Journal of experimental medicine.
[15] C. Smith,et al. Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.
[16] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[17] Fengzhi Li,et al. Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.
[18] J C Reed,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.
[19] D. S. Yu,et al. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. , 1998, British journal of urology.
[20] T. Griffith,et al. TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.
[21] J. Tschopp,et al. Inhibition of fas death signals by FLIPs. , 1998, Current opinion in immunology.
[22] T. Griffith,et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.
[23] D. Ferrari,et al. Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.
[24] D. Altieri,et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.
[25] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[26] E. Eneroth,et al. Preeclampsia and Maternal Heart Rate Variability , 1998, Gynecologic and Obstetric Investigation.
[27] D. Altieri,et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.
[28] A. Gurney,et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.
[29] J. Tschopp,et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.
[30] L. Hood,et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. , 1997, Immunity.
[31] C. Smith,et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.
[32] R. Dubose,et al. Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.
[33] Henning Walczak,et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.
[34] W I Wood,et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.
[35] R. Gentz,et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.
[36] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[37] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[38] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[39] D. Vaux,et al. The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. , 1997, Seminars in immunology.
[40] D. Vaux,et al. Effects of viral inhibitors of apoptosis in models of mammalian cell death. , 1996, Behring Institute Mitteilungen.
[41] S. Marsters,et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.
[42] T. Deguchi,et al. Detection of Low‐level Expression of P‐Glycoprotein in ACHN Renal Adenocarcinoma Cells , 1996, Japanese journal of cancer research : Gann.
[43] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[44] D. Green,et al. Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.
[45] D. Green,et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.
[46] M. Lenardo,et al. Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.
[47] D. Recine,et al. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. , 1995, Seminars in oncology.
[48] S. Dower,et al. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. , 1995, Blood.
[49] S. Nagata,et al. Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.
[50] H. Steller. Mechanisms and genes of cellular suicide , 1995, Science.
[51] D. Petrylak,et al. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.
[52] C. Smith,et al. Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.
[53] R. Armitage. Tumor necrosis factor receptor superfamily members and their ligands. , 1994, Current opinion in immunology.
[54] D. A. Flick,et al. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. , 1984, Journal of immunological methods.
[55] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[56] P. Grundy,et al. The survivin:fas ratio in pediatric renal tumors. , 2001, Journal of pediatric surgery.
[57] A. Ravaud,et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.
[58] D. Cosman. A family of ligands for the TNF receptor superfamily , 1994, Stem cells.
[59] G. Haas,et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. , 1992, The Journal of urology.
[60] P. Alken,et al. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. , 1990, Urologia internationalis.
[61] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[62] B. Beutler,et al. The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.